CriticalReversible MAO-A inhibitor (RIMA)×Triptan, selective 5HT1B/1D receptor agonist
Updated · Methodology
Mechanism
Moclobemide reversibly inhibits monoamine oxidase (MAO), mainly type A, and slows the breakdown of noradrenaline, dopamine and serotonin (moclobemide summary of product characteristics, SmPC, section 5.1). Naratriptan stimulates serotonin 5-HT1B and 5-HT1D receptors, which take part in the constriction of intracranial blood vessels (naratriptan SmPC, section 5.1). The moclobemide SmPC contraindicates all triptans because MAO and cytochrome P450 enzymes break them down, so their concentrations rise with moclobemide. Naratriptan is among the examples it names (section 4.5). The naratriptan SmPC describes a different picture. Many cytochrome P450 enzymes take part in its limited metabolism, and naratriptan did not inhibit MAO in vitro. For that reason, no in vivo interaction studies with MAO inhibitors were done, and the SmPC gives no data on higher naratriptan levels with moclobemide (sections 4.5 and 5.2). The US Food and Drug Administration (FDA) naratriptan label names MAO inhibitors among the drugs with which serotonin syndrome may occur (section 5.7).
Symptoms
The prescribing information does not describe how this particular combination presents. With monoamine oxidase (MAO) inhibitors, serotonin syndrome may occur: agitation, hallucinations, coma, fast heart rate, labile blood pressure, high temperature, overactive reflexes, poor coordination, nausea, vomiting and diarrhoea. It usually starts within minutes to hours of a new or higher dose of a serotonergic drug (naratriptan label, US Food and Drug Administration, FDA, section 5.7). Naratriptan itself can cause pain, heaviness, pressure or tightness in any part of the body, including the chest and throat, and these sensations are sometimes intense. Within 12 hours of a dose, blood pressure may rise by about 5 mmHg systolic and 3 mmHg diastolic (naratriptan summary of product characteristics, SmPC, sections 4.4 and 4.8). On rare occasions triptans have caused a marked rise in blood pressure, up to hypertensive crisis with acute impairment of organ systems, including in people with no history of hypertension (FDA naratriptan label, section 5.8).
Management
The combination is contraindicated. The moclobemide summary of product characteristics (SmPC) contraindicates triptans as a group and names naratriptan explicitly (sections 4.3 and 4.5). The Spanish naratriptan SmPC and the US Food and Drug Administration (FDA) naratriptan label do not list monoamine oxidase (MAO) inhibitors among their contraindications. The contraindication in the moclobemide SmPC still applies, so do not prescribe naratriptan and moclobemide together. No document gives an interval between stopping moclobemide and the first dose of naratriptan, or for the opposite switch. If the two drugs have nevertheless been taken together and signs of serotonin syndrome appear, stop naratriptan (FDA naratriptan label, section 5.7). For moclobemide, consider a lower dose or stopping it, depending on how severe the symptoms are (moclobemide SmPC, section 4.4). Monitor blood pressure during naratriptan treatment (FDA naratriptan label, section 5.8). Naratriptan is contraindicated in moderate or severe hypertension and in uncontrolled mild hypertension (naratriptan SmPC, section 4.3). If chest pain and tightness suggest cardiac ischaemia, withhold further naratriptan doses and assess the patient (naratriptan SmPC, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Naratriptán (nº registro 61828), sección 4.3 (2023)– AEMPS, CIMA, nº registro 61828 (Naramig 2,5 mg, Glaxo), revisión 11/2023 (fecha del documento en CIMA; la sección 10 indica junio 2020), secciones 4.3, 4.4 y 4.5
- FDA: Naratriptan tablets, Bionpharma (naratriptan) prescribing information (2026)– FDA, DailyMed setid 93b7e6c2-e6a7-4f6b-9ecd-62d6bb0a6dda, revisión 06/2026 (versión 4), secciones 4, 5.1–5.8 y 7.1
- AEMPS: Ficha técnica: Moclobemida, Manerix 300 mg (nº registro 60824) (2025)– AEMPS, CIMA, nº registro 60824 (Manerix 300 mg comprimidos recubiertos con película), revisión 06/2025, secciones 4.3, 4.5, 5.1 y 5.2